Siren LLC’s Hemab Therapeutics COAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$73M Buy
2,366,235
+279,401
+13% +$12.3M 1.72% 16
2026
Q2
$76.6M Buy
+2,086,834
New +$57.6M 1.55% 19

Other funds holding COAG

Siren LLC's COAG Position: Q3 2026 in Review

Siren LLC increased its Hemab Therapeutics (COAG) stake by 13% in Q3 2026, buying an estimated $12.3M and bringing the position to 2,366,235 shares worth $73M. The position accounts for 1.72% of the portfolio, ranked #16.

Siren LLC first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $76.6M in Q2 2026. 89 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • Siren LLC held 2,366,235 shares of Hemab Therapeutics worth $73M as of Q3 2026.
  • Siren LLC bought 279,401 Hemab Therapeutics shares in Q3 2026, an estimated $12.3M.
  • Hemab Therapeutics made up 1.72% of Siren LLC's portfolio in Q3 2026, its #16 holding.
  • Siren LLC first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Siren LLC's Hemab Therapeutics position peaked at $76.6M in Q2 2026.
  • 89 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Siren LLC's 13F filing for Q3 2026, filed 12 Nov 2026.